The Nobel Assembly at Karolinska Institutet announced the award of the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, Peter Hegemann, and Georg Nagel for discoveries that established light-gated ion channels as tools for controlling defined populations of neurons, giving rise to optogenetics. Hegemann and Nagel's channelrhodopsin discoveries in Germany laid the foundation for Deisseroth's 2005 work at Stanford demonstrating that the proteins could be used to control mammalian neurons with light.
The prize recognizes the discovery and development of channelrhodopsins, light-gated ion channels found in the green alga Chlamydomonas reinhardtii, and their transformation into a method that allows researchers to activate or silence specific neuronal populations with millisecond precision using light. The approach gave neuroscientists a way to test whether particular cells and circuits are necessary or sufficient for behaviors, moving beyond the less selective effects of electrical stimulation and pharmacologic interventions.
Hegemann's group had observed that light-induced currents in Chlamydomonas occurred within microseconds, suggesting that the photoreceptor and ion channel could be part of the same protein. Nagel, Hegemann, and colleagues subsequently showed that channelrhodopsin-1 was itself a light-gated ion channel, followed by characterization of channelrhodopsin-2 as a blue-light-activated cation channel.
The critical step toward modern optogenetics came in 2005, when Deisseroth, then at Stanford University, and colleagues expressed channelrhodopsin-2 in cultured rat hippocampal neurons and demonstrated that brief pulses of blue light could trigger action potentials with millisecond precision. Mammalian tissue contained sufficient endogenous retinal to activate the channel, helping make the approach practical for use in living systems.
The optogenetic toolkit subsequently expanded to include inhibitory proteins such as halorhodopsin and anion channelrhodopsins, allowing researchers to both activate and silence genetically defined cell populations. The technology has since been used to dissect neural circuits involved in sleep, fear, reward, anxiety, and movement, becoming a standard experimental approach in systems neuroscience.
Clinical translation has advanced furthest in retinal disease, where surviving retinal neurons can be genetically engineered to become light-sensitive after loss of native photoreceptors. Early proof-of-concept came from a 2021 Nature Medicine report in which a patient with advanced retinitis pigmentosa regained partial visual function after receiving an AAV vector encoding the red-shifted opsin ChrimsonR and using engineered light-stimulating goggles.